Travere Therapeutics Announces Q1 2026 Earnings Results and Filspari FDA Approval
Travere Therapeutics (TVTX) reported Q1 2026 earnings, highlighting the FDA approval of Filspari for FSGS and strong sales growth. The company estimates over 100,000 U.S. patients eligible for Filspari and forecasts $3 billion in peak sales potential. Total revenue reached $127.2 million, driven by Filspari's 88% year-over-year sales increase.
Topics: FDA Approval Filspari FSGS Pharmaceuticals Revenue Growth